78095-35-9

Usage

Uses

Used in Pharmaceutical Development:
(S)-8-methoxy-N-propyl-2-aminotetraline hydrochloride is used as a therapeutic agent for the treatment of neurodegenerative disorders, particularly Parkinson's disease. It acts as a dopamine receptor agonist, helping to alleviate symptoms and improve the quality of life for patients.
Used in Scientific Research:
(S)-8-methoxy-N-propyl-2-aminotetraline hydrochloride is used as a reference standard in laboratory experiments to help researchers understand the effects of dopamine receptor activation and study the mechanisms of action of related compounds. It aids in the development of new drugs and therapies targeting the dopaminergic system.
Used in Neurological and Psychiatric Conditions:
(S)-8-methoxy-N-propyl-2-aminotetraline hydrochloride is also investigated for its potential as a therapeutic agent for other neurological and psychiatric conditions, where dopamine receptor activation may play a role in treatment.
Used in Studying Neurotransmitter Function:
(S)-8-methoxy-N-propyl-2-aminotetraline hydrochloride is used to study the function of neurotransmitters, particularly dopamine, and its role in various brain functions and disorders. This helps researchers identify potential drug targets and develop more effective treatments for related conditions.

Upstream product

• 81185-31-1 Benzyl-((S)-8-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine; hydrochloride 
• 1256261-04-7 (3aS,9bR)-9-methoxy-3-propyl-3,3a,4,5-tetrahydronaphtho[2,1-d]oxazol-2(9bH)-one 
• 79-03-8 propionyl chloride 
• 81185-18-4 Benzyl-(8-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amine 
• 81185-19-5 N-benzyl-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 
• 81185-18-4 Benzyl-(8-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-amine 

Downstream Products

• 76135-31-4 (-)-8-hydroxy-2-(di-n-propylamino)tetralin*HBr 
• 76135-31-4 (+)-8-hydroxy-2(di-N-propylamino)-tetralin hydrobromide 
• 119432-89-2 (S)-8-Methoxy-DPAT 

Relevant academic research and scientific papers

Practical asymmetric synthesis of bioactive aminotetralins from a racemic precursor using a regiodivergent resolution

Catalyst-controlled asymmetric ring opening of a racemic oxabicyclic alkene leads to two readily separable regioisomeric products both in excellent ee. A cationic Rh catalyst, with added NH4BF4 to modulate reactivity, was required to obtain synthetically useful yields. The utility of each substituted aminotetralin product has been demonstrated by their conversion to different biologically relevant molecules in a highly efficient and practical manner.

8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists

A series of 2-(alkylamino)tetralins related to 8-hydroxy-2-(di-n-propylamino)tetralin (21) were prepared and tested as dopamine (DA) and 5-hydroxytryptamine (5-HT) receptor agonists. Several of the compounds were potent 5-HT agonists devoid of DA-mimetic effects. N-Ethyl or N-propyl substitution of 8-hydroxy-2-aminotetralin gave the most potent agonists. It was shown that the most potent compound, (+)-21, has the 2R configuration. 5,8-Dimethoxy-2-(di-n-propylamino)tetralin (31) was found to be a weak DA agonist devoid of 5-HT activity. The corresponding indan derivative, 4,7-dimethoxy-2-(di-n-propylamino)indan (39), has been reported to be active on both DA and 5-HT receptors. The 5-HT-stimulating properties of compounds 21 and 39 as compared to the incapability of compound 31 to activate the 5-HT receptor is tentatively explained by the assumed mode of binding of the compounds to the 5-HT receptor.